Murrayafoline A
Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF) -stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS -induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer[1][2][3][4].
Product Specifications
CAS Number
4532-33-6
UNSPSC
12352005
Hazard Statement
H341, H351, H413
Target
IKK; Interleukin Related; JNK; NF-κB; p38 MAPK; Wnt; β-catenin
Type
Natural Products
Related Pathways
Immunology/Inflammation; MAPK/ERK Pathway; NF-κB; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/murrayafoline-a.html
Purity
99.73
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CC1=CC2=C(C(=C1)OC)NC3=CC=CC=C23
Molecular Formula
C14H13NO
Molecular Weight
211.26
Precautions
H341, H351, H413
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Natural Products
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lentiviral human PRPF19 shRNA (UAS) - Lentiviral human PRPF19 shRNA (UAS, RFP) (25)
